FDA OKs new administration options for GSK’s Nucala
The two new methods, autoinjector and a pre-filled safety syringe, are for patients or caregivers to administer once every four weeks.
Read More
Tag: anti-IL5 biologic
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
